Spero Therapeutics Inc’s recent filing unveils that its Chief Operating Officer Keutzer Timothy unloaded Company’s shares for reported $44099.0 on Feb 05 ’25. In the deal valued at $0.78 per share,56,537 shares were sold. As a result of this transaction, Keutzer Timothy now holds 741,439 shares worth roughly $2.11 million.
Then, Rajavelu Esther sold 20,689 shares, generating $16,137 in total proceeds. Upon selling the shares at $0.78, the CFO & CBO now owns 724,720 shares.
Before that, Shukla Sath sold 155,333 shares. Spero Therapeutics Inc shares valued at $121,160 were divested by the CEO & President at a price of $0.78 per share. As a result of the transaction, Shukla Sath now holds 1,736,883 shares, worth roughly $4.95 million.
Evercore ISI downgraded its Spero Therapeutics Inc [SPRO] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in late September from “an In-line” to “an Outperform”. Oppenheimer also remained covering SPRO and has decreased its forecast on October 01, 2021 with a “Perform” recommendation from previously “an Outperform” rating. H.C. Wainwright maintained its rating on January 22, 2021. It rated SPRO as “a Buy”.
Price Performance Review of SPRO
On Monday, Spero Therapeutics Inc [NASDAQ:SPRO] saw its stock jump 0.71% to $2.85. Over the last five days, the stock has gained 3.26%. Spero Therapeutics Inc shares have risen nearly 176.70% since the year began. Nevertheless, the stocks have risen 99.30% over the past one year. While a 52-week high of $3.06 was reached on 06/12/25, a 52-week low of $0.51 was recorded on 04/09/25.
Levels Of Support And Resistance For SPRO Stock
The 24-hour chart illustrates a support level at 2.80, which if violated will result in even more drops to 2.76. On the upside, there is a resistance level at 2.92. A further resistance level may holdings at 3.00.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $47 price target.
